Iradimed Co Stock Performance
| IRMD Stock | USD 52.30 1.17 2.19% |
The company retains a Market Volatility (i.e., Beta) of 0.76, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Iradimed's returns are expected to increase less than the market. However, during the bear market, the loss of holding Iradimed is expected to be smaller as well. At this point, Iradimed has a negative expected return of -0.26%. Please make sure to check out Iradimed's value at risk, and the relationship between the jensen alpha and accumulation distribution , to decide if Iradimed performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Iradimed Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in June 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (2.19) | Five Day Return (0.48) | Year To Date Return (4.81) | Ten Year Return 226.06 | All Time Return 428.28 |
Forward Dividend Yield 0.0127 | Payout Ratio | Forward Dividend Rate 0.68 | Dividend Date 2025-03-05 | Ex Dividend Date 2025-02-24 |
1 | Q4 2024 IRadimed Corp Earnings Call Transcript | 02/14/2025 |
| Iradimed dividend paid on 5th of March 2025 | 03/05/2025 |
3 | Acquisition by Hawkins James B of 1036 shares of Iradimed subject to Rule 16b-3 | 03/14/2025 |
4 | Disposition of 5796 shares by John Glenn of Iradimed subject to Rule 16b-3 | 04/07/2025 |
5 | Integer Beats Q1 Earnings and Revenue Estimates | 04/24/2025 |
6 | IRADIMED outlines Q2 2025 revenue guidance of 19.7M-19.9M amid strong pump shipments | 05/05/2025 |
| Begin Period Cash Flow | 49.8 M |
Iradimed Relative Risk vs. Return Landscape
If you would invest 6,248 in Iradimed Co on February 5, 2025 and sell it today you would lose (1,018) from holding Iradimed Co or give up 16.29% of portfolio value over 90 days. Iradimed Co is currently does not generate positive expected returns and assumes 2.0999% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Iradimed, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Iradimed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iradimed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Iradimed Co, and traders can use it to determine the average amount a Iradimed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IRMD |
Estimated Market Risk
| 2.1 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Iradimed is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Iradimed by adding Iradimed to a well-diversified portfolio.
Iradimed Fundamentals Growth
Iradimed Stock prices reflect investors' perceptions of the future prospects and financial health of Iradimed, and Iradimed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Iradimed Stock performance.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 627.8 M | ||||
| Shares Outstanding | 12.72 M | ||||
| Price To Earning | 28.70 X | ||||
| Price To Book | 7.75 X | ||||
| Price To Sales | 9.19 X | ||||
| Revenue | 73.24 M | ||||
| Gross Profit | 56.35 M | ||||
| EBITDA | 22.78 M | ||||
| Net Income | 19.23 M | ||||
| Cash And Equivalents | 55.59 M | ||||
| Cash Per Share | 4.42 X | ||||
| Total Debt | 154.69 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.83 X | ||||
| Book Value Per Share | 6.83 X | ||||
| Cash Flow From Operations | 25.62 M | ||||
| Earnings Per Share | 1.50 X | ||||
| Market Capitalization | 665 M | ||||
| Total Asset | 98.33 M | ||||
| Retained Earnings | 56.79 M | ||||
| Working Capital | 66.73 M | ||||
| Current Asset | 33.95 M | ||||
| Current Liabilities | 2.89 M | ||||
About Iradimed Performance
By analyzing Iradimed's fundamental ratios, stakeholders can gain valuable insights into Iradimed's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Iradimed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Iradimed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 224.76 | 164.78 | |
| Return On Tangible Assets | 0.20 | 0.17 | |
| Return On Capital Employed | 0.24 | 0.24 | |
| Return On Assets | 0.20 | 0.17 | |
| Return On Equity | 0.22 | 0.20 |
Things to note about Iradimed performance evaluation
Checking the ongoing alerts about Iradimed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Iradimed help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Iradimed generated a negative expected return over the last 90 days | |
| About 59.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: IRADIMED outlines Q2 2025 revenue guidance of 19.7M-19.9M amid strong pump shipments |
- Analyzing Iradimed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Iradimed's stock is overvalued or undervalued compared to its peers.
- Examining Iradimed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Iradimed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Iradimed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Iradimed's stock. These opinions can provide insight into Iradimed's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Iradimed Stock analysis
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |